RU-57073: Difference between revisions
Content deleted Content added
| Line 39: | Line 39: | ||
* [[Nilutamide]] |
* [[Nilutamide]] |
||
* [[RU-56187]] |
* [[RU-56187]] |
||
| ⚫ | |||
* [[RU-58642]] |
* [[RU-58642]] |
||
| ⚫ | |||
* [[RU-59063]] |
* [[RU-59063]] |
||
Revision as of 13:34, 25 December 2018
| Names | |
|---|---|
| IUPAC name
4-[3-(2-hydroxyethyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
| |
| Identifiers | |
3D model (JSmol)
|
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C15H14F3N3O2S | |
| Molar mass | 357.351 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
RU-57073 is a nonsteroidal antiandrogen which was never marketed.[1][2][3] It shows 163% of the affinity of testosterone for the androgen receptor and negligible affinity for other steroid hormone receptors.[1][2]
Template:Affinities of a selection of androgen ligands at steroid hormone receptors
See also
References
- ^ a b Singh SM, Gauthier S, Labrie F (February 2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
- ^ a b Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, Philibert D (January 1994). "Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor". J. Steroid Biochem. Mol. Biol. 48 (1): 111–9. doi:10.1016/0960-0760(94)90257-7. PMID 8136296.
- ^ Münster U, Nakamura C, Haberland A, Jores K, Mehnert W, Rummel S, Schaller M, Korting HC, Zouboulis CC, Blume-Peytavi U, Schäfer-Korting M (January 2005). "RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia". Pharmazie. 60 (1): 8–12. PMID 15700772.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |